Azar’s Drug Dispute Panel Picks Nixed by Biden Administration

Jan. 22, 2021, 11:11 PM

The Biden administration has withdrawn appointments to a long-awaited forum for resolving drug discount fights just over a week after the process took effect.

Withdrawal of the Department of Health and Human Services’ public notice, which had named agency members to the administrative panel, effectively halts disputes from being carried out, policy watchers say.

An HHS rule in December established the panel to settle disputes under the federal 340B program, which requires companies to offer steep discounts to hospitals with primarily low-income patients. That rule took effect Jan. 13, and there has so far been at least one filing—against AstraZeneca ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.